Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 12/20 | 0.38 |
| ▸ | HTR2B | P41595 | 4/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3453581 | 1.00 | SPR (0.38) | SPRHTR2BNAMPTCALCRLHPGD | |
| SCHEMBL3452487 | 0.95 | SPR (0.38) | SPRHTR2BNAMPTCALCRLHPGD | |
| SCHEMBL2022110 | 0.88 | HTR2B (0.34) | SPRHTR2BNAMPT | |
| SCHEMBL2022111 | 0.88 | HTR2B (0.34) | SPRHTR2BNAMPT | |
| SCHEMBL16333592 | 0.86 | SPR (0.36) | SPRHTR2BNAMPT | |
| SCHEMBL12432341 | 0.86 | SPR (0.36) | SPRHTR2BNAMPT | |
| SCHEMBL2210084 | 0.86 | SPR (0.36) | SPRHTR2BNAMPT | |
| SCHEMBL13109206 | 0.84 | ROCK2 (0.36) | NAMPT | |
| SCHEMBL3454076 | 0.84 | POLB (0.34) | HTR2BNAMPTHPGD | |
| SCHEMBL3454079 | 0.84 | POLB (0.34) | HTR2BNAMPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029576-B1 | CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2013-06-19 | — | — | EP | claimed |
| US-7820659-B2 | Cyclohexylimidiazole lactam derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-10-26 | — | — | US | claimed |
| US-20090088428-A1 | CYCLOHEXYLIMIDIAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-02 | — | — | US | claimed |
| EP-2029576-A1 | CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Eli Lilly & Company (US) | 2009-03-04 | — | — | EP | claimed |
| WO-2007124329-A1 | CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | WO | claimed |
| US-8871208-B2 | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof | ABBVIE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2029576-B1 | CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-7820659-B2 | Cyclohexylimidiazole lactam derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-10-26 | — | — | US | disclosed |
| US-20090088428-A1 | CYCLOHEXYLIMIDIAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-02 | — | — | US | disclosed |
| EP-2029576-A1 | CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Eli Lilly & Company (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007124329-A1 | CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | SPR 203/4885HTR2B 823/4885NAMPT 861/4885 |
| US-20090088428-A1 | CYCLOHEXYLIMIDIAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD11B2 | SPR 180/4885HTR2B 1153/4885NAMPT 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.